Background:   The inter-α trypsin inhibitor (ITI) family is a group of structurally related plasma serine protease inhibitors synthesized in the liver and built up from different combinations of three highly homologous heavy chains (ITI-HI, ITI-H2 and ITI-H3) and one light chain (bikunin). A fourth member of the ITI family, ITI-H4 (also known as I α IH4P) harbours a Pro-rich region (PRR) in its c-terminus. ITI (also known as IaI) is a 220 kDa glycoprotein composed of three polypeptides linked by chondroitin sulphate: two heavy chains, ITI-H1 (65kDa) and ITI-H2 (70 kDa), and bikunin (approx. 30 kDa). Bikunin confers the protease-inhibitor function of ITI. The heavy chains of the ITI family, designated as SHAPs (for serum-derived hyaluronan-associated proteins), bind covalently to hyaluronic acid (HA), resulting in pericellular matrix stabilization. ITI-H1 contains a potential peptide which could stimulate a broad spectrum of phagocytotic cells. Although ITI-H1, ITI-H3 and bikunin have antitumoral and antimetastatic properties in the cell, they are also associated with malignant transformation of lung tissue. ITI family members, ITI-H1 and ITIH2, are associated with calcium oxalate stone formation in kidney and urine. The human ITI-H1 gene maps to chromosome 3p21.2-p21.1 and encodes a 180 kDa protein.

Description: Rabbit polyclonal to ITIH2

Immunogen: KLH conjugated synthetic peptide derived from ITIH2

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 106 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/50-200;

·Immunocytochemistry/Immunofluorescence: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.